LLASHNEWSMedical aesthetics media & sourcingRequest Quote
Company NewsAesthetic Devices

【South Korea】Lameditech Selected for South Korea's 'K-Beauty' National R&D Project, Advances AI-Based Laser Drug Delivery Platform

Source image preserved for article context.
Editor's note

This development signals a strategic shift from device manufacturing to platform integration. Buyer relevance is high, as the LADD platform promises compatibility with various biomaterials. The regulatory question centers on the 2026 certification timeline for upgraded lasers. Supply-chain risk is mitigated by in-sourcing allogeneic ECM, a key regenerative component.

Laser medical aesthetics device specialist Lameditech has been selected for the 'K-Beauty' track of the Ministry of SMEs and Startups' 'SME Technology Innovation Development Project'. The project aims to develop a smart skin assessment device with personalized deep-learning skin analysis and a miniaturized fractional Er:YAG laser device. Lameditech will use this to advance its Laser-Assisted Drug Delivery (LADD) system, combining AI skin analysis with ultra-compact fractional Er:YAG laser technology.

The company plans to expand LADD beyond a single laser device into an open drug delivery platform compatible with various biomaterials and skin boosters. Notably, Lameditech is integrating its allogeneic ECM (extracellular matrix) business, which involves collagen and elastin—key structural components for regenerative and medical aesthetics applications. The allogeneic ECM will be developed as a regenerative biomaterial for the LADD platform, alongside hyaluronic acid, growth factors, and peptides, to create differentiated medical aesthetics solutions combining laser devices and biomaterials.

Lameditech expects to complete medical device certification for its upgraded laser devices in the second half of 2026, accelerating entry into the dermatology and medical aesthetics market. Concurrently, it will lay the groundwork for LADD platform commercialization and biomaterial-linked business expansion.

A Lameditech representative stated: "This project selection marks a critical leap for Lameditech from a simple laser medical aesthetics device company to an AI-based laser drug delivery platform company. We will expand LADD platform commercialization through market entry in H2 2026, platform commercialization in 2027, and technology advancement by 2028."

The representative added: "By linking various regenerative biomaterials, including allogeneic ECM, and skin booster materials to the LADD platform, we will secure new growth drivers in the domestic and international medical aesthetics and medical device markets."

Source: Read the original report | Published: May 18, 2026